12 Results for "

heart failure with preserved ejection fraction

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "heart failure with preserved ejection fraction" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-145581
CAS No.: 1933460-19-5
Purity:  99.12%
Synonyms: AZD4831
Mitiperstat (AZD4831) is an effective oral inhibitor of myeloperoxidase (MPO). Mitiperstat inhibits MPO and thyroid peroxidase (TPO) with IC50s of 1.5 nM and 0.69 μM. Mitiperstat exhibits a weak inhibitory activity against CYP3A4 with an IC50 of 6 μM. Mitiperstat can reduce inflammation and improve microvascular function, and it can be used in studies related to heart failure, preserved or mildly reduced ejection fraction, non-alcoholic fatty liver disease, and chronic obstructive pulmonary disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-109136
CAS No.: 1402936-61-1
Purity:  99.31%
Synonyms: BAY 1101042
Runcaciguat (BAY 1101042) is a selective, orally active, allosteric activator of soluble guanylate cyclase (sGC) that specifically targets its oxidized and heme-free form. Runcaciguat binds to sGC in a histidine-dependent manner and restores cyclic guanosine monophosphate (cGMP) production under oxidative stress, independent of nitric oxide (NO) or heme. Runcaciguat exhibits renoprotective and cardioprotective activities, such as reduced proteinuria and improved renal function. Runcaciguat is primarily being studied in chronic kidney disease (CKD) associated with hypertension, diabetes, and metabolic disorders, as well as potential cardiovascular indications such as heart failure with preserved ejection fraction (HFpEF) .
loading...
    loading...
Cat. No.: HY-175747
CAS No.: 3036759-47-1
Target:  

AMPK

Research Areas:  

Cardiovascular Disease

PF-07293893 is an AMPKγ3 activator. PF-07293893 increases glycogen content, improves lipid oxidation, enhances mitochondrial biogenesis and promotes vascular repair. PF-07293893 is applicable to research related to heart failure .
loading...
    loading...
Cat. No.: HY-164027
CAS No.: 2614161-13-4
Target:  

E1/E2/E3 Enzyme

Research Areas:  

Metabolic Disease Cancer

MyoMed 205 is an orally active muscle ring finger protein 1 (MuRF1) inhibitor. MyoMed-205 reduces ubiquitination and subsequent proteasomal degradation of muscle proteins by inhibiting MuRF1 activity. MyoMed 205 augments muscle performance, attenuates muscle weight loss and alleviates disease-induced weight loss. MyoMed 205 can be used for the research of cancer cachexia, type 2 diabetes mellitus, and heart failure with preserved ejection fraction .
loading...
    loading...
Cat. No.: HY-120274
CAS No.: 1850385-64-6
Purity:  99.96%
Synonyms: AZD9977
Balcinrenone (AZD9977) is an orally active mineralocorticoid receptor modulator. Balcinrenone regulates mineralocorticoid receptor activity, inhibits aldosterone-induced target gene expression, and suppresses the activities of renal Toll-like receptor 4, MyD88 and NF-κB. Balcinrenone alleviates renal extracellular matrix remodeling, inflammatory cell infiltration, and the expression of renal injury markers. Balcinrenone restores myocardial perfusion reserve, regulates potassium homeostasis, and induces fecal potassium excretion. Balcinrenone is applicable to research on metabolism-related chronic kidney disease and heart failure .
loading...
    loading...
Cat. No.: HY-172424
CAS No.: 2417411-02-8
Target:  

Myosin

Research Areas:  

Cardiovascular Disease

Delocamten is an orally active, selective Cardiac Myosin inhibitor with an IC50 of approximately 1.11 μM. Delocamten directly modulates myosin complexes, inhibits excessive myocardial contraction, and improves diastolic function. Delocamten can be used in studies of hypertrophic cardiomyopathy (HCM), left ventricular hypertrophy, and diastolic dysfunction .
loading...
    loading...
Cat. No.: HY-176233
CAS No.: 2765296-93-1
Target:  

Transthyretin (TTR)

Research Areas:  

Cardiovascular Disease

Transthyretin-IN-4 (Compound B26) is a bivalent inhibitor of transthyretin (TTR) amyloidosis (bIC50: 0.09 µM, pIC50: 1.4 µM). Transthyretin-IN-4 is used in the study of fatal heart failure with preserved ejection fraction (HFpEF) and fatal arrhythmias .
loading...
    loading...
Cat. No.: HY-P11861
CNP analogue-1 is a long-acting, low-isoelectric point C-type natriuretic peptide (CNP) analog. CNP analogue-1 activates human natriuretic peptide receptor 2 (hNPR2) with an EC50 of 0.18 nM. CNP analogue-1 stimulates cGMP production and is resistant to neprilysin-mediated degradation. CNP analogue-1 induces baroreceptor-mediated heart rate elevation and enhances the maximal rates of cardiac contraction and relaxation. CNP analogue-1 can be used in the research of heart failure with preserved ejection fraction .
loading...
    loading...
Cat. No.: HY-145581B
CAS No.: 1933460-18-4
Synonyms: (rac)-AZD4831
(rac)-Mitiperstat ((rac)-AZD4831) is the racemic form of Mitiperstat (HY-145581). Mitiperstat (AZD4831) is an effective oral inhibitor of myeloperoxidase (MPO). Mitiperstat inhibits MPO and thyroid peroxidase (TPO) with IC50s of 1.5 nM and 0.69 μM. Mitiperstat exhibits a weak inhibitory activity against CYP3A4 with an IC50 of 6 μM. Mitiperstat can reduce inflammation and improve microvascular function, and it can be used in studies related to heart failure, preserved or mildly reduced ejection fraction, non-alcoholic fatty liver disease, and chronic obstructive pulmonary disease .
loading...
    loading...
Cat. No.: HY-145581S
Synonyms: AZD4831-d3
Mitiperstat-d3 (AZD4831-d3) is the deuterated -labeled Mitiperstat (HY-145581).Mitiperstat (AZD4831) is an effective oral inhibitor of myeloperoxidase (MPO). Mitiperstat inhibits MPO and thyroid peroxidase (TPO) with IC50s of 1.5 nM and 0.69 μM. Mitiperstat exhibits a weak inhibitory activity against CYP3A4 with an IC50 of 6 μM. Mitiperstat can reduce inflammation and improve microvascular function, and it can be used in studies related to heart failure, preserved or mildly reduced ejection fraction, non-alcoholic fatty liver disease, and chronic obstructive pulmonary disease .
loading...
    loading...
Cat. No.: HY-109136R
CAS No.: 1402936-61-1
Synonyms: BAY 1101042 (Standard)
Runcaciguat (Standard) is the analytical standard of Runcaciguat (HY-109136). This product is intended for research and analytical applications. Runcaciguat (BAY 1101042) is a selective, orally active, allosteric activator of soluble guanylate cyclase (sGC) that specifically targets its oxidized and heme-free form. Runcaciguat binds to sGC in a histidine-dependent manner and restores cyclic guanosine monophosphate (cGMP) production under oxidative stress, independent of nitric oxide (NO) or heme. Runcaciguat exhibits renoprotective and cardioprotective activities, such as reduced proteinuria and improved renal function. Runcaciguat is primarily being studied in chronic Kidney disease (CKd) associated with hypertension, diabetes, and metabolic disorders, as well as potential cardiovascular indications such as heart failure with preserved ejection fraction (HFpEF) .
loading...
    loading...
Cat. No.: HY-120274A
CAS No.: 1850385-65-7
Synonyms: (R)-AZD9977
(R)-Balcinrenone ((R)-AZD9977) is an isomer of Balcinrenone (HY-120274). Balcinrenone is an orally active mineralocorticoid receptor modulator. Balcinrenone regulates mineralocorticoid receptor activity, inhibits aldosterone-induced target gene expression, and suppresses the activities of renal Toll-like receptor 4, MyD88 and NF-κB. Balcinrenone alleviates renal extracellular matrix remodeling, inflammatory cell infiltration, and the expression of renal injury markers. Balcinrenone restores myocardial perfusion reserve, regulates potassium homeostasis, and induces fecal potassium excretion. Balcinrenone is applicable to research on metabolism-related chronic kidney disease and heart failure .
loading...
    loading...
  • 1